Integrum (OM:INTEG B) - Stock Price, News & Analysis

INTEG B Stock Overview

Researches, develops, and sells various systems for bone-anchored prostheses.

INTEG B fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 75% below our estimate of its fair value

Earnings are forecast to grow 60.72% per year

Became profitable this year

Risk Analysis

High level of non-cash earnings

Does not have a meaningful market cap (SEK929M)

Shareholders have been diluted in the past year

Integrum AB (publ) Competitors

Paxman

OM:PAX

SEK 984.8m

C-Rad

OM:CRAD B

SEK 1.4b

Senzime

OM:SEZI

SEK 955.3m

ADDvise Group

OM:ADDV A

SEK 1.2b

Price History & Performance

Summary of all time highs, changes and price drops for Integrum
Historical stock prices
Current Share Price	SEK 47.90
52 Week High	SEK 64.00
52 Week Low	SEK 16.40
Beta	1.78
11 Month Change	-17.41%
3 Month Change	-6.45%
1 Year Change	143.64%
33 Year Change	-36.97%
5 Year Change	438.20%
Change since IPO	112.89%

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

May 03

Recent updates

Shareholder Returns

	INTEG B	SE Medical Equipment	SE Market
7D	-2.2%	-6.8%	-6.7%
1Y	143.6%	-2.8%	9.9%

Return vs Industry: INTEG B exceeded the Swedish Medical Equipment industry which returned -0% over the past year.

Return vs Market: INTEG B exceeded the Swedish Market which returned 12.6% over the past year.

Price Volatility

Is INTEG B's price volatile compared to industry and market?
INTEG B volatility
INTEG B Average Weekly Movement	6.8%
Medical Equipment Industry Average Movement	7.2%
Market Average Movement	5.9%
10% most volatile stocks in SE Market	12.2%
10% least volatile stocks in SE Market	3.5%

Stable Share Price: INTEG B has not had significant price volatility in the past 3 months.

Volatility Over Time: INTEG B's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1962	36	Rickard Branemark	www.integrum.se

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads.

Integrum AB (publ) Fundamentals Summary

How do Integrum's earnings and revenue compare to its market cap?
INTEG B fundamental statistics
Market cap	SEK 929.11m
Earnings (TTM)	SEK 4.17m
Revenue (TTM)	SEK 110.46m

222.6x

P/E Ratio

8.4x

P/S Ratio

Is INTEG B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INTEG B income statement (TTM)
Revenue	SEK 110.46m
Cost of Revenue	SEK 19.20m
Gross Profit	SEK 91.26m
Other Expenses	SEK 87.09m
Earnings	SEK 4.17m

Last Reported Earnings

Apr 30, 2024

Next Earnings Date

Aug 29, 2024

Earnings per share (EPS)	0.22
Gross Margin	82.62%
Net Profit Margin	3.78%
Debt/Equity Ratio	0%

How did INTEG B perform over the long term?

See historical performance and comparison

INTEG B Stock Overview

Rewards

Risk Analysis

Integrum AB (publ) Competitors

OM:PAX

SEK 984.8m

OM:CRAD B

SEK 1.4b

OM:SEZI

SEK 955.3m

OM:ADDV A

SEK 1.2b

Price History & Performance

Recent News & Updates

Consensus EPS estimates fall by 37%, revenue upgraded

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Price target increased by 7.3% to kr77.25

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

Recent updates

Consensus EPS estimates fall by 37%, revenue upgraded

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Price target increased by 7.3% to kr77.25

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

Consensus revenue estimates decrease by 12%

Price target decreased by 31% to kr72.00

New minor risk - Share price stability

Full year 2023 earnings: Revenues miss analyst expectations

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Consensus revenue estimates decrease by 40%

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Consensus forecasts updated

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Does Integrum (STO:INTEG B) Deserve A Spot On Your Watchlist?

First quarter 2023 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q2, 2023 Results on Dec 05, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Price target decreased to kr100.00

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Owner & Chairman exercised options to buy kr1.4m worth of stock.